Based on an authorization from the Extraordinary General Meeting on September 10, 2018, the Board of Directors of STENOCARE A/S (“STENOCARE” or “the Company”) has issued 88,977 warrant to GEMSTONE Capital as described in the Memorandum. Gemstone Capital has decided to exercise 45,000 warrants at the agreed price of DKK 8.80 per share. Thus, STENOCARE is provided DKK 396,000 in new share capital.
The Memorandum describe the decision to issue warrants for GEMSTONE Capital Aps. Based on an authorization from the Extraordinary General Meeting on September 10, 2018, the Board of Directors of STENOCARE has decided to issue warrants to Gemstone Capital. The warrants give Gemstone Capital the right to a total of 88,977 shares, equivalent to 1 percent of the total number of shares in the Company after the listing on Spotlight Stock market. Each warrant entitles Gemstone Capital the right to subscribe for one new share in the Company at a subscription price of DKK 8.80. The remaining warrants can be exercised anytime over a five-year period from the first day of trading on Spotlight Stock Market, i.e. the 26th of October 2018.
In connection with the Board of Director’s decision of granting and issuing warrants, Gemstone Capital has decided to exercise 45,000 warrants at the agreed subscription price of DKK 8.80 per share. Thus, Gemstone Capital acquires 45,000 shares in STENOCARE, corresponding to DKK 396,000. When the warrants have been exercised and the new shares have been registered at Erhvervsstyrelsen, Gemstone Capital will have a total of 45,000 shares in STENOCARE and 43,977 warrants remaining. When the shares are registered, the total number of shares in STENOCARE will amount to a total of 8,942,762 shares and the share capital will amount to a total of DKK 715,420.96.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on October 29, 2018.
STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot programme. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers high quality pharmaceutical grade medical cannabis oil, which is produced by hygienic and high technology cultivation and processing without the use of pesticides. STENOCARE will also develop a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.